speb/financial-data huggingface dataset:
ADVENZYMES.NS balance_sheet (quarterly, 2025-09-30) — Other Intangible Assets: 504340000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-09-30) — Other Non Current Assets: 60670000.00
ADVENZYMES.NS income_statement (quarterly, 2025-09-30) — Other Non Operating Income Expenses: 102840000.00
ADVENZYMES.NS income_statement (quarterly, 2025-09-30) — Other Operating Expenses: 405330000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-09-30) — Other Properties: 2844470000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-09-30) — Other Receivables: 2850000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-09-30) — Other Short Term Investments: 5566540000.00
ADVENZYMES.NS income_statement (quarterly, 2025-09-30) — Otherunder Preferred Stock Dividend: 0.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-09-30) — Payables: 305970000.00
ADVENZYMES.NS income_statement (quarterly, 2025-09-30) — Pretax Income: 595410000.00
ADVENZYMES.NS income_statement (quarterly, 2025-09-30) — Reconciled Cost Of Revenue: 445670000.00
ADVENZYMES.NS income_statement (quarterly, 2025-09-30) — Reconciled Depreciation: 100760000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-09-30) — Share Issued: 111881150.00
ADVENZYMES.NS income_statement (quarterly, 2025-09-30) — Special Income Charges: 0.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-09-30) — Stockholders Equity: 14845450000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-09-30) — Tangible Book Value: 10860240000.00
ADVENZYMES.NS income_statement (quarterly, 2025-09-30) — Tax Effect Of Unusual Items: 0.00
ADVENZYMES.NS income_statement (quarterly, 2025-09-30) — Tax Provision: 148080000.00
ADVENZYMES.NS income_statement (quarterly, 2025-09-30) — Tax Rate For Calcs: 0.25
ADVENZYMES.NS balance_sheet (quarterly, 2025-09-30) — Total Assets: 16918960000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-09-30) — Total Capitalization: 14932340000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-09-30) — Total Debt: 346540000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-09-30) — Total Equity Gross Minority Interest: 15335700000.00
ADVENZYMES.NS income_statement (quarterly, 2025-09-30) — Total Expenses: 1345490000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-09-30) — Total Liabilities Net Minority Interest: 1583260000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-09-30) — Total Non Current Assets: 7584360000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-09-30) — Total Non Current Liabilities Net Minority Interest: 515950000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-09-30) — Total Tax Payable: 12960000.00
ADVENZYMES.NS income_statement (quarterly, 2025-09-30) — Total Unusual Items: 0.00
ADVENZYMES.NS income_statement (quarterly, 2025-09-30) — Total Unusual Items Excluding Goodwill: 0.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-09-30) — Working Capital: 8267290000.00
ADVENZYMES.NS income_statement (quarterly, 2025-12-31) — +Operating Expense: 913990000.00
ADVENZYMES.NS income_statement (quarterly, 2025-12-31) — +Total Revenue: 1719490000.00
ADVENZYMES.NS income_statement (quarterly, 2025-12-31) — Basic Average Shares: 111842105.00
ADVENZYMES.NS income_statement (quarterly, 2025-12-31) — Basic EPS: 3.80
ADVENZYMES.NS income_statement (quarterly, 2025-12-31) — Cost Of Revenue: 414060000.00
ADVENZYMES.NS income_statement (quarterly, 2025-12-31) — Depreciation And Amortization In Income Statement: 102060000.00
ADVENZYMES.NS income_statement (quarterly, 2025-12-31) — Depreciation Income Statement: 102060000.00
ADVENZYMES.NS income_statement (quarterly, 2025-12-31) — Diluted Average Shares: 112137203.00
ADVENZYMES.NS income_statement (quarterly, 2025-12-31) — Diluted EPS: 3.79
ADVENZYMES.NS income_statement (quarterly, 2025-12-31) — Diluted NI Availto Com Stockholders: 425000000.00
ADVENZYMES.NS income_statement (quarterly, 2025-12-31) — EBIT: 588590000.00
ADVENZYMES.NS income_statement (quarterly, 2025-12-31) — EBITDA: 690650000.00
ADVENZYMES.NS income_statement (quarterly, 2025-12-31) — Gross Profit: 1305430000.00
ADVENZYMES.NS income_statement (quarterly, 2025-12-31) — Interest Expense: 5680000.00
ADVENZYMES.NS income_statement (quarterly, 2025-12-31) — Interest Expense Non Operating: 5680000.00
ADVENZYMES.NS income_statement (quarterly, 2025-12-31) — Minority Interests: -6830000.00
ADVENZYMES.NS income_statement (quarterly, 2025-12-31) — Net Income: 425000000.00
ADVENZYMES.NS income_statement (quarterly, 2025-12-31) — Net Income Common Stockholders: 425000000.00
ADVENZYMES.NS income_statement (quarterly, 2025-12-31) — Net Income Continuous Operations: 431830000.00
ADVENZYMES.NS income_statement (quarterly, 2025-12-31) — Net Income From Continuing And Discontinued Operation: 425000000.00
ADVENZYMES.NS income_statement (quarterly, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: 425000000.00
ADVENZYMES.NS income_statement (quarterly, 2025-12-31) — Net Income Including Noncontrolling Interests: 431830000.00
ADVENZYMES.NS income_statement (quarterly, 2025-12-31) — Net Interest Income: -5680000.00
ADVENZYMES.NS income_statement (quarterly, 2025-12-31) — Net Non Operating Interest Income Expense: -5680000.00
ADVENZYMES.NS income_statement (quarterly, 2025-12-31) — Normalized EBITDA: 578190000.00
ADVENZYMES.NS income_statement (quarterly, 2025-12-31) — Normalized Income: 341687650.24
ADVENZYMES.NS income_statement (quarterly, 2025-12-31) — Operating Income: 391440000.00
ADVENZYMES.NS income_statement (quarterly, 2025-12-31) — Operating Revenue: 1719490000.00
ADVENZYMES.NS income_statement (quarterly, 2025-12-31) — Other Non Operating Income Expenses: 84690000.00
ADVENZYMES.NS income_statement (quarterly, 2025-12-31) — Other Operating Expenses: 399310000.00
ADVENZYMES.NS income_statement (quarterly, 2025-12-31) — Otherunder Preferred Stock Dividend: 0.00
ADVENZYMES.NS income_statement (quarterly, 2025-12-31) — Pretax Income: 582910000.00
ADVENZYMES.NS income_statement (quarterly, 2025-12-31) — Reconciled Cost Of Revenue: 414060000.00
ADVENZYMES.NS income_statement (quarterly, 2025-12-31) — Reconciled Depreciation: 102060000.00
ADVENZYMES.NS income_statement (quarterly, 2025-12-31) — Special Income Charges: 112460000.00
ADVENZYMES.NS income_statement (quarterly, 2025-12-31) — Tax Effect Of Unusual Items: 29147650.24
ADVENZYMES.NS income_statement (quarterly, 2025-12-31) — Tax Provision: 151080000.00
ADVENZYMES.NS income_statement (quarterly, 2025-12-31) — Tax Rate For Calcs: 0.26
ADVENZYMES.NS income_statement (quarterly, 2025-12-31) — Total Expenses: 1328050000.00
ADVENZYMES.NS income_statement (quarterly, 2025-12-31) — Total Unusual Items: 112460000.00
ADVENZYMES.NS income_statement (quarterly, 2025-12-31) — Total Unusual Items Excluding Goodwill: 112460000.00
ADVENZYMES.NS income_statement (annual, 2026-03-31) — +Operating Expense: 3459060000.00
ADVENZYMES.NS income_statement (quarterly, 2026-03-31) — +Operating Expense: 934010000.00
ADVENZYMES.NS income_statement (annual, 2026-03-31) — +Total Revenue: 7449500000.00
ADVENZYMES.NS income_statement (quarterly, 2026-03-31) — +Total Revenue: 2033670000.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Accounts Payable: 399590000.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Accounts Payable: 399590000.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Accounts Receivable: 1450200000.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Accounts Receivable: 1450200000.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Accumulated Depreciation: -2446080000.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Accumulated Depreciation: -2446080000.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Additional Paid In Capital: 856180000.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Additional Paid In Capital: 856180000.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Allowance For Doubtful Accounts Receivable: -12110000.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Allowance For Doubtful Accounts Receivable: -12110000.00
ADVENZYMES.NS income_statement (annual, 2026-03-31) — Amortization: 90260000.00
ADVENZYMES.NS cash_flow (annual, 2026-03-31) — Amortization Cash Flow: 90260000.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Available For Sale Securities: 50070000.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Available For Sale Securities: 50070000.00
ADVENZYMES.NS income_statement (quarterly, 2026-03-31) — Basic Average Shares: 111882812.00
ADVENZYMES.NS income_statement (quarterly, 2026-03-31) — Basic EPS: 3.84
ADVENZYMES.NS cash_flow (annual, 2026-03-31) — Beginning Cash Position: 942250000.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Buildings And Improvements: 1550720000.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Buildings And Improvements: 1550720000.00
ADVENZYMES.NS cash_flow (annual, 2026-03-31) — Capital Expenditure: -523770000.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Capital Lease Obligations: 114810000.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Capital Lease Obligations: 114810000.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Capital Stock: 223850000.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Capital Stock: 223850000.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Cash And Cash Equivalents: 1087550000.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Cash And Cash Equivalents: 1087550000.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 7071960000.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 7071960000.00
ADVENZYMES.NS cash_flow (annual, 2026-03-31) — Cash Dividends Paid: -597780000.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Cash Equivalents: 589920000.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Cash Equivalents: 589920000.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Cash Financial: 497630000.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Cash Financial: 497630000.00
ADVENZYMES.NS cash_flow (annual, 2026-03-31) — Change In Inventory: -162470000.00
ADVENZYMES.NS cash_flow (annual, 2026-03-31) — Change In Other Current Assets: -14560000.00
ADVENZYMES.NS cash_flow (annual, 2026-03-31) — Change In Other Current Liabilities: 39350000.00
ADVENZYMES.NS cash_flow (annual, 2026-03-31) — Change In Payable: 194720000.00
ADVENZYMES.NS cash_flow (annual, 2026-03-31) — Change In Receivables: -261000000.00
ADVENZYMES.NS cash_flow (annual, 2026-03-31) — Change In Working Capital: -145490000.00
ADVENZYMES.NS cash_flow (annual, 2026-03-31) — Changes In Cash: 122800000.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Common Stock: 223850000.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Common Stock: 223850000.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Common Stock Equity: 16319570000.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Common Stock Equity: 16319570000.00
ADVENZYMES.NS cash_flow (annual, 2026-03-31) — Common Stock Issuance: 9530000.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Construction In Progress: 511690000.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Construction In Progress: 511690000.00
ADVENZYMES.NS income_statement (annual, 2026-03-31) — Cost Of Revenue: 2069700000.00
ADVENZYMES.NS income_statement (quarterly, 2026-03-31) — Cost Of Revenue: 569300000.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Current Assets: 10435740000.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Current Assets: 10435740000.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Current Capital Lease Obligation: 77120000.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Current Capital Lease Obligation: 77120000.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Current Debt: 126410000.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Current Debt: 126410000.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Current Debt And Capital Lease Obligation: 203530000.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Current Debt And Capital Lease Obligation: 203530000.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Current Liabilities: 1067220000.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Current Liabilities: 1067220000.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Current Provisions: 63940000.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Current Provisions: 63940000.00
ADVENZYMES.NS cash_flow (annual, 2026-03-31) — Depreciation: 310670000.00
ADVENZYMES.NS cash_flow (annual, 2026-03-31) — Depreciation And Amortization: 400930000.00
ADVENZYMES.NS income_statement (annual, 2026-03-31) — Depreciation And Amortization In Income Statement: 400930000.00
ADVENZYMES.NS income_statement (quarterly, 2026-03-31) — Depreciation And Amortization In Income Statement: 101920000.00
ADVENZYMES.NS income_statement (annual, 2026-03-31) — Depreciation Income Statement: 310670000.00
ADVENZYMES.NS income_statement (quarterly, 2026-03-31) — Depreciation Income Statement: 101920000.00
ADVENZYMES.NS income_statement (quarterly, 2026-03-31) — Diluted Average Shares: 111882812.00
ADVENZYMES.NS income_statement (quarterly, 2026-03-31) — Diluted EPS: 3.84
ADVENZYMES.NS income_statement (annual, 2026-03-31) — Diluted NI Availto Com Stockholders: 1687190000.00
ADVENZYMES.NS income_statement (quarterly, 2026-03-31) — Diluted NI Availto Com Stockholders: 429630000.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Dividends Payable: 2360000.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Dividends Payable: 2360000.00
ADVENZYMES.NS income_statement (annual, 2026-03-31) — EBIT: 2351640000.00
ADVENZYMES.NS income_statement (quarterly, 2026-03-31) — EBIT: 603770000.00
ADVENZYMES.NS income_statement (annual, 2026-03-31) — EBITDA: 2752570000.00
ADVENZYMES.NS income_statement (quarterly, 2026-03-31) — EBITDA: 705690000.00
ADVENZYMES.NS cash_flow (annual, 2026-03-31) — Effect Of Exchange Rate Changes: 22500000.00
ADVENZYMES.NS cash_flow (annual, 2026-03-31) — End Cash Position: 1087550000.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 640000.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 640000.00
ADVENZYMES.NS cash_flow (annual, 2026-03-31) — Financing Cash Flow: -703660000.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Finished Goods: 373260000.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Finished Goods: 373260000.00
ADVENZYMES.NS cash_flow (annual, 2026-03-31) — Free Cash Flow: 1043990000.00
ADVENZYMES.NS cash_flow (annual, 2026-03-31) — Gain Loss On Investment Securities: -96570000.00
ADVENZYMES.NS cash_flow (annual, 2026-03-31) — Gain Loss On Sale Of PPE: 1040000.00
ADVENZYMES.NS income_statement (annual, 2026-03-31) — General And Administrative Expense: 217220000.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Goodwill: 3694600000.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Goodwill: 3694600000.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Goodwill And Other Intangible Assets: 4163820000.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Goodwill And Other Intangible Assets: 4163820000.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Gross Accounts Receivable: 1462310000.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Gross Accounts Receivable: 1462310000.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Gross PPE: 5716100000.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Gross PPE: 5716100000.00
ADVENZYMES.NS income_statement (annual, 2026-03-31) — Gross Profit: 5379800000.00
ADVENZYMES.NS income_statement (quarterly, 2026-03-31) — Gross Profit: 1464370000.00
ADVENZYMES.NS income_statement (annual, 2026-03-31) — Impairment Of Capital Assets: 3630000.00
ADVENZYMES.NS income_statement (annual, 2026-03-31) — Interest Expense: 26280000.00
ADVENZYMES.NS income_statement (quarterly, 2026-03-31) — Interest Expense: 5730000.00
ADVENZYMES.NS income_statement (annual, 2026-03-31) — Interest Expense Non Operating: 26280000.00
ADVENZYMES.NS income_statement (quarterly, 2026-03-31) — Interest Expense Non Operating: 5730000.00
ADVENZYMES.NS income_statement (annual, 2026-03-31) — Interest Income: 179980000.00
ADVENZYMES.NS income_statement (annual, 2026-03-31) — Interest Income Non Operating: 179980000.00
ADVENZYMES.NS cash_flow (annual, 2026-03-31) — Interest Paid Cff: -24210000.00
ADVENZYMES.NS cash_flow (annual, 2026-03-31) — Interest Received Cfi: 182090000.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Inventory: 1772770000.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Inventory: 1772770000.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Invested Capital: 16524850000.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Invested Capital: 16524850000.00
ADVENZYMES.NS cash_flow (annual, 2026-03-31) — Investing Cash Flow: -741300000.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Investmentin Financial Assets: 50710000.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Investmentin Financial Assets: 50710000.00
ADVENZYMES.NS cash_flow (annual, 2026-03-31) — Issuance Of Capital Stock: 9530000.00
ADVENZYMES.NS cash_flow (annual, 2026-03-31) — Issuance Of Debt: 2780000.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Land And Improvements: 587050000.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Land And Improvements: 587050000.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Long Term Capital Lease Obligation: 37690000.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Long Term Capital Lease Obligation: 37690000.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Long Term Debt: 78870000.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Long Term Debt: 78870000.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 116560000.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 116560000.00
ADVENZYMES.NS cash_flow (annual, 2026-03-31) — Long Term Debt Payments: -12860000.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Long Term Provisions: 53880000.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Long Term Provisions: 53880000.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Machinery Furniture Equipment: 3066640000.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Machinery Furniture Equipment: 3066640000.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Minority Interest: 511650000.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Minority Interest: 511650000.00
ADVENZYMES.NS income_statement (annual, 2026-03-31) — Minority Interests: -48890000.00
ADVENZYMES.NS income_statement (quarterly, 2026-03-31) — Minority Interests: -22890000.00
ADVENZYMES.NS cash_flow (annual, 2026-03-31) — Net Common Stock Issuance: 9530000.00
ADVENZYMES.NS cash_flow (annual, 2026-03-31) — Net Foreign Currency Exchange Gain Loss: -4260000.00
ADVENZYMES.NS income_statement (annual, 2026-03-31) — Net Income: 1687190000.00
ADVENZYMES.NS income_statement (quarterly, 2026-03-31) — Net Income: 429630000.00
ADVENZYMES.NS income_statement (annual, 2026-03-31) — Net Income Common Stockholders: 1687190000.00
ADVENZYMES.NS income_statement (quarterly, 2026-03-31) — Net Income Common Stockholders: 429630000.00
ADVENZYMES.NS income_statement (annual, 2026-03-31) — Net Income Continuous Operations: 1736080000.00
ADVENZYMES.NS income_statement (quarterly, 2026-03-31) — Net Income Continuous Operations: 452520000.00
ADVENZYMES.NS income_statement (annual, 2026-03-31) — Net Income From Continuing And Discontinued Operation: 1687190000.00
ADVENZYMES.NS income_statement (quarterly, 2026-03-31) — Net Income From Continuing And Discontinued Operation: 429630000.00
ADVENZYMES.NS income_statement (annual, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: 1687190000.00
ADVENZYMES.NS income_statement (quarterly, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: 429630000.00
ADVENZYMES.NS cash_flow (annual, 2026-03-31) — Net Income From Continuing Operations: 2325360000.00
ADVENZYMES.NS income_statement (annual, 2026-03-31) — Net Income Including Noncontrolling Interests: 1736080000.00
ADVENZYMES.NS income_statement (quarterly, 2026-03-31) — Net Income Including Noncontrolling Interests: 452520000.00
ADVENZYMES.NS cash_flow (annual, 2026-03-31) — Net Intangibles Purchase And Sale: -1470000.00
ADVENZYMES.NS income_statement (annual, 2026-03-31) — Net Interest Income: 142640000.00
ADVENZYMES.NS income_statement (quarterly, 2026-03-31) — Net Interest Income: -5730000.00
ADVENZYMES.NS cash_flow (annual, 2026-03-31) — Net Investment Purchase And Sale: -404090000.00
ADVENZYMES.NS cash_flow (annual, 2026-03-31) — Net Issuance Payments Of Debt: -10080000.00
ADVENZYMES.NS cash_flow (annual, 2026-03-31) — Net Long Term Debt Issuance: -12860000.00
ADVENZYMES.NS income_statement (annual, 2026-03-31) — Net Non Operating Interest Income Expense: 142640000.00
ADVENZYMES.NS income_statement (quarterly, 2026-03-31) — Net Non Operating Interest Income Expense: -5730000.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Net PPE: 3270020000.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Net PPE: 3270020000.00
ADVENZYMES.NS cash_flow (annual, 2026-03-31) — Net PPE Purchase And Sale: -517830000.00
ADVENZYMES.NS cash_flow (annual, 2026-03-31) — Net Short Term Debt Issuance: 2780000.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Net Tangible Assets: 12155750000.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Net Tangible Assets: 12155750000.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Non Current Deferred Taxes Assets: 48780000.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Assets: 48780000.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Non Current Deferred Taxes Liabilities: 318730000.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Liabilities: 318730000.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 53880000.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 53880000.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Non Current Prepaid Assets: 186960000.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Non Current Prepaid Assets: 186960000.00
ADVENZYMES.NS income_statement (annual, 2026-03-31) — Normalized EBITDA: 2585420000.00
ADVENZYMES.NS income_statement (quarterly, 2026-03-31) — Normalized EBITDA: 704560000.00
ADVENZYMES.NS income_statement (annual, 2026-03-31) — Normalized Income: 1562398237.86
ADVENZYMES.NS income_statement (quarterly, 2026-03-31) — Normalized Income: 428774960.87
ADVENZYMES.NS cash_flow (annual, 2026-03-31) — Operating Cash Flow: 1567760000.00
ADVENZYMES.NS income_statement (annual, 2026-03-31) — Operating Income: 1920740000.00
ADVENZYMES.NS income_statement (quarterly, 2026-03-31) — Operating Income: 530360000.00
ADVENZYMES.NS income_statement (annual, 2026-03-31) — Operating Revenue: 7449500000.00
ADVENZYMES.NS income_statement (quarterly, 2026-03-31) — Operating Revenue: 2033670000.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Ordinary Shares Number: 111926800.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Ordinary Shares Number: 111926800.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Other Current Assets: 17450000.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Other Current Assets: 17450000.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Other Current Liabilities: 104940000.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Other Current Liabilities: 104940000.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Other Equity Interest: 91590000.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Other Equity Interest: 91590000.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Other Intangible Assets: 469220000.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Other Intangible Assets: 469220000.00
ADVENZYMES.NS cash_flow (annual, 2026-03-31) — Other Non Cash Items: -160160000.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Other Non Current Assets: 300000.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Other Non Current Assets: 300000.00
ADVENZYMES.NS income_statement (annual, 2026-03-31) — Other Non Operating Income Expenses: 75280000.00
ADVENZYMES.NS income_statement (quarterly, 2026-03-31) — Other Non Operating Income Expenses: 72280000.00
ADVENZYMES.NS income_statement (annual, 2026-03-31) — Other Operating Expenses: 887860000.00
ADVENZYMES.NS income_statement (quarterly, 2026-03-31) — Other Operating Expenses: 412710000.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Other Payable: 309300000.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Other Payable: 309300000.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Other Properties: 2758320000.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Other Properties: 2758320000.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Other Receivables: 9820000.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Other Receivables: 9820000.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Other Short Term Investments: 5984410000.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Other Short Term Investments: 5984410000.00
ADVENZYMES.NS income_statement (annual, 2026-03-31) — Other Special Charges: -112550000.00
ADVENZYMES.NS income_statement (annual, 2026-03-31) — Otherunder Preferred Stock Dividend: 0.00
ADVENZYMES.NS income_statement (quarterly, 2026-03-31) — Otherunder Preferred Stock Dividend: 0.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Payables: 721390000.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Payables: 721390000.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Prepaid Assets: 109030000.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Prepaid Assets: 109030000.00
ADVENZYMES.NS income_statement (annual, 2026-03-31) — Pretax Income: 2325360000.00
ADVENZYMES.NS income_statement (quarterly, 2026-03-31) — Pretax Income: 598040000.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Properties: 0.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Properties: 0.00
ADVENZYMES.NS cash_flow (annual, 2026-03-31) — Provisionand Write Offof Assets: -157690000.00
ADVENZYMES.NS cash_flow (annual, 2026-03-31) — Purchase Of Intangibles: -1470000.00
ADVENZYMES.NS cash_flow (annual, 2026-03-31) — Purchase Of Investment: -484620000.00
ADVENZYMES.NS cash_flow (annual, 2026-03-31) — Purchase Of PPE: -522300000.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Raw Materials: 936830000.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Raw Materials: 936830000.00
ADVENZYMES.NS income_statement (annual, 2026-03-31) — Reconciled Cost Of Revenue: 2069700000.00
ADVENZYMES.NS income_statement (quarterly, 2026-03-31) — Reconciled Cost Of Revenue: 569300000.00
ADVENZYMES.NS income_statement (annual, 2026-03-31) — Reconciled Depreciation: 400930000.00
ADVENZYMES.NS income_statement (quarterly, 2026-03-31) — Reconciled Depreciation: 101920000.00
ADVENZYMES.NS income_statement (annual, 2026-03-31) — Rent And Landing Fees: 83100000.00
ADVENZYMES.NS income_statement (annual, 2026-03-31) — Rent Expense Supplemental: 83100000.00
ADVENZYMES.NS cash_flow (annual, 2026-03-31) — Repayment Of Debt: -12860000.00
ADVENZYMES.NS income_statement (annual, 2026-03-31) — Research And Development: 14200000.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Restricted Cash: 4510000.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Restricted Cash: 4510000.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Retained Earnings: 12645540000.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Retained Earnings: 12645540000.00
ADVENZYMES.NS cash_flow (annual, 2026-03-31) — Sale Of Investment: 80530000.00
ADVENZYMES.NS cash_flow (annual, 2026-03-31) — Sale Of PPE: 4470000.00
ADVENZYMES.NS income_statement (annual, 2026-03-31) — Selling And Marketing Expense: 231940000.00
ADVENZYMES.NS income_statement (annual, 2026-03-31) — Selling General And Administration: 449160000.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Share Issued: 111926800.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Share Issued: 111926800.00
ADVENZYMES.NS cash_flow (annual, 2026-03-31) — Short Term Debt Issuance: 2780000.00
ADVENZYMES.NS income_statement (annual, 2026-03-31) — Special Income Charges: 94150000.00
ADVENZYMES.NS income_statement (quarterly, 2026-03-31) — Special Income Charges: 1130000.00
ADVENZYMES.NS cash_flow (annual, 2026-03-31) — Stock Based Compensation: 48600000.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Stockholders Equity: 16319570000.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Stockholders Equity: 16319570000.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Tangible Book Value: 12155750000.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Tangible Book Value: 12155750000.00
ADVENZYMES.NS income_statement (annual, 2026-03-31) — Tax Effect Of Unusual Items: 42358237.86
ADVENZYMES.NS income_statement (quarterly, 2026-03-31) — Tax Effect Of Unusual Items: 274960.87
ADVENZYMES.NS income_statement (annual, 2026-03-31) — Tax Provision: 589280000.00
ADVENZYMES.NS income_statement (quarterly, 2026-03-31) — Tax Provision: 145520000.00
ADVENZYMES.NS income_statement (annual, 2026-03-31) — Tax Rate For Calcs: 0.25
ADVENZYMES.NS income_statement (quarterly, 2026-03-31) — Tax Rate For Calcs: 0.24
ADVENZYMES.NS cash_flow (annual, 2026-03-31) — Taxes Refund Paid: -651270000.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Total Assets: 18387610000.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Total Assets: 18387610000.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Total Capitalization: 16398440000.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Total Capitalization: 16398440000.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Total Debt: 320090000.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Total Debt: 320090000.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Total Equity Gross Minority Interest: 16831220000.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Total Equity Gross Minority Interest: 16831220000.00
ADVENZYMES.NS income_statement (annual, 2026-03-31) — Total Expenses: 5528760000.00
ADVENZYMES.NS income_statement (quarterly, 2026-03-31) — Total Expenses: 1503310000.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Total Liabilities Net Minority Interest: 1556390000.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Total Liabilities Net Minority Interest: 1556390000.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Total Non Current Assets: 7951880000.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Total Non Current Assets: 7951880000.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 489170000.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 489170000.00
ADVENZYMES.NS income_statement (annual, 2026-03-31) — Total Other Finance Cost: 11060000.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Total Tax Payable: 10140000.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Total Tax Payable: 10140000.00
ADVENZYMES.NS income_statement (annual, 2026-03-31) — Total Unusual Items: 167150000.00
ADVENZYMES.NS income_statement (quarterly, 2026-03-31) — Total Unusual Items: 1130000.00
ADVENZYMES.NS income_statement (annual, 2026-03-31) — Total Unusual Items Excluding Goodwill: 167150000.00
ADVENZYMES.NS income_statement (quarterly, 2026-03-31) — Total Unusual Items Excluding Goodwill: 1130000.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Work In Process: 462680000.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Work In Process: 462680000.00
ADVENZYMES.NS balance_sheet (annual, 2026-03-31) — Working Capital: 9368520000.00
ADVENZYMES.NS balance_sheet (quarterly, 2026-03-31) — Working Capital: 9368520000.00
ADVENZYMES.NS income_statement (annual, 2026-03-31) — Write Off: 14770000.00
ADVN.SW income_statement (annual, 2021-12-31) — Basic Average Shares: 730000.00
ADVN.SW income_statement (annual, 2021-12-31) — Basic EPS: 8.05
ADVN.SW cash_flow (annual, 2021-12-31) — Capital Expenditure Reported: -3672000.00
ADVN.SW cash_flow (annual, 2021-12-31) — Cash Dividends Paid: -985000.00
ADVN.SW cash_flow (annual, 2021-12-31) — Change In Prepaid Assets: 7719000.00
ADVN.SW cash_flow (annual, 2021-12-31) — Common Stock Dividend Paid: -985000.00
ADVN.SW balance_sheet (annual, 2021-12-31) — Current Debt: 0.00
ADVN.SW income_statement (annual, 2021-12-31) — Diluted Average Shares: 730000.00
ADVN.SW income_statement (annual, 2021-12-31) — Diluted EPS: 8.05
ADVN.SW cash_flow (annual, 2021-12-31) — Net Common Stock Issuance: 0.00
ADVN.SW cash_flow (annual, 2021-12-31) — Net Investment Purchase And Sale: -22000.00
ADVN.SW cash_flow (annual, 2021-12-31) — Net Issuance Payments Of Debt: -536000.00
ADVN.SW cash_flow (annual, 2021-12-31) — Net Long Term Debt Issuance: -379000.00
ADVN.SW cash_flow (annual, 2021-12-31) — Net Short Term Debt Issuance: -157000.00
ADVN.SW cash_flow (annual, 2021-12-31) — Purchase Of Investment: -22000.00
ADVN.SW income_statement (annual, 2021-12-31) — Restructuring And Mergern Acquisition: -303000.00
ADVN.SW cash_flow (annual, 2021-12-31) — Sale Of Investment: 0.00
ADVN.SW balance_sheet (annual, 2021-12-31) — Treasury Shares Number: 96.00
ADVN.SW balance_sheet (annual, 2021-12-31) — Treasury Stock: 17000.00
ADVN.SW income_statement (annual, 2022-12-31) — +Operating Expense: 75982000.00
ADVN.SW income_statement (annual, 2022-12-31) — +Total Revenue: 178365000.00
ADVN.SW balance_sheet (annual, 2022-12-31) — Accounts Payable: 12648000.00
ADVN.SW balance_sheet (annual, 2022-12-31) — Accounts Receivable: 25987000.00
ADVN.SW balance_sheet (annual, 2022-12-31) — Accumulated Depreciation: -141851000.00
ADVN.SW balance_sheet (annual, 2022-12-31) — Allowance For Doubtful Accounts Receivable: -1292000.00
ADVN.SW income_statement (annual, 2022-12-31) — Amortization: 776000.00
ADVN.SW cash_flow (annual, 2022-12-31) — Amortization Cash Flow: 776000.00
ADVN.SW income_statement (annual, 2022-12-31) — Basic Average Shares: 730000.00
ADVN.SW income_statement (annual, 2022-12-31) — Basic EPS: -3.22
ADVN.SW cash_flow (annual, 2022-12-31) — Beginning Cash Position: 31946000.00
ADVN.SW balance_sheet (annual, 2022-12-31) — Buildings And Improvements: 52954000.00
ADVN.SW cash_flow (annual, 2022-12-31) — Capital Expenditure: -3081000.00
ADVN.SW cash_flow (annual, 2022-12-31) — Capital Expenditure Reported: -2980000.00
ADVN.SW balance_sheet (annual, 2022-12-31) — Capital Lease Obligations: 445000.00
ADVN.SW balance_sheet (annual, 2022-12-31) — Capital Stock: 14600000.00
ADVN.SW balance_sheet (annual, 2022-12-31) — Cash And Cash Equivalents: 28601000.00
ADVN.SW balance_sheet (annual, 2022-12-31) — Cash Cash Equivalents And Short Term Investments: 28601000.00
ADVN.SW cash_flow (annual, 2022-12-31) — Cash Dividends Paid: -1460000.00
ADVN.SW balance_sheet (annual, 2022-12-31) — Cash Equivalents: 11917000.00
ADVN.SW balance_sheet (annual, 2022-12-31) — Cash Financial: 16684000.00
ADVN.SW cash_flow (annual, 2022-12-31) — Change In Inventory: -11834000.00
ADVN.SW cash_flow (annual, 2022-12-31) — Change In Other Current Liabilities: 6390000.00
ADVN.SW cash_flow (annual, 2022-12-31) — Change In Payable: 2933000.00
ADVN.SW cash_flow (annual, 2022-12-31) — Change In Prepaid Assets: 39000.00
ADVN.SW cash_flow (annual, 2022-12-31) — Change In Receivables: -2007000.00
ADVN.SW cash_flow (annual, 2022-12-31) — Change In Working Capital: -4479000.00
ADVN.SW cash_flow (annual, 2022-12-31) — Changes In Cash: -3263000.00
ADVN.SW balance_sheet (annual, 2022-12-31) — Common Stock: 14600000.00
ADVN.SW cash_flow (annual, 2022-12-31) — Common Stock Dividend Paid: -1460000.00
ADVN.SW balance_sheet (annual, 2022-12-31) — Common Stock Equity: 121377000.00
ADVN.SW balance_sheet (annual, 2022-12-31) — Construction In Progress: 2142000.00
ADVN.SW income_statement (annual, 2022-12-31) — Cost Of Revenue: 101849000.00
ADVN.SW balance_sheet (annual, 2022-12-31) — Current Assets: 109939000.00
ADVN.SW balance_sheet (annual, 2022-12-31) — Current Capital Lease Obligation: 220000.00
ADVN.SW balance_sheet (annual, 2022-12-31) — Current Debt And Capital Lease Obligation: 220000.00
ADVN.SW balance_sheet (annual, 2022-12-31) — Current Liabilities: 40459000.00
ADVN.SW balance_sheet (annual, 2022-12-31) — Current Provisions: 187000.00
ADVN.SW cash_flow (annual, 2022-12-31) — Deferred Tax: 235000.00
ADVN.SW cash_flow (annual, 2022-12-31) — Depreciation: 6956000.00
ADVN.SW cash_flow (annual, 2022-12-31) — Depreciation And Amortization: 7732000.00
ADVN.SW income_statement (annual, 2022-12-31) — Depreciation And Amortization In Income Statement: 7732000.00
ADVN.SW income_statement (annual, 2022-12-31) — Depreciation Income Statement: 6956000.00
ADVN.SW income_statement (annual, 2022-12-31) — Diluted Average Shares: 730000.00
ADVN.SW income_statement (annual, 2022-12-31) — Diluted EPS: -3.22
ADVN.SW income_statement (annual, 2022-12-31) — Diluted NI Availto Com Stockholders: -2348000.00
ADVN.SW income_statement (annual, 2022-12-31) — EBIT: -470000.00
ADVN.SW income_statement (annual, 2022-12-31) — EBITDA: 7262000.00
ADVN.SW cash_flow (annual, 2022-12-31) — Effect Of Exchange Rate Changes: -82000.00
ADVN.SW cash_flow (annual, 2022-12-31) — End Cash Position: 28601000.00
ADVN.SW cash_flow (annual, 2022-12-31) — Financing Cash Flow: -1804000.00
ADVN.SW balance_sheet (annual, 2022-12-31) — Finished Goods: 83000.00
ADVN.SW cash_flow (annual, 2022-12-31) — Free Cash Flow: -1518000.00
ADVN.SW cash_flow (annual, 2022-12-31) — Gain Loss On Sale Of PPE: -59000.00
ADVN.SW income_statement (annual, 2022-12-31) — General And Administrative Expense: 5546000.00
ADVN.SW balance_sheet (annual, 2022-12-31) — Goodwill And Other Intangible Assets: 866000.00
ADVN.SW balance_sheet (annual, 2022-12-31) — Gross Accounts Receivable: 27279000.00
ADVN.SW balance_sheet (annual, 2022-12-31) — Gross PPE: 194298000.00
ADVN.SW income_statement (annual, 2022-12-31) — Gross Profit: 76516000.00
ADVN.SW balance_sheet (annual, 2022-12-31) — Hedging Assets Current: 0.00
ADVN.SW income_statement (annual, 2022-12-31) — Interest Expense: 62000.00
ADVN.SW income_statement (annual, 2022-12-31) — Interest Expense Non Operating: 62000.00
ADVN.SW income_statement (annual, 2022-12-31) — Interest Income: 191000.00
ADVN.SW income_statement (annual, 2022-12-31) — Interest Income Non Operating: 191000.00
ADVN.SW balance_sheet (annual, 2022-12-31) — Inventories Adjustments Allowances: -10642000.00
ADVN.SW balance_sheet (annual, 2022-12-31) — Inventory: 49960000.00
ADVN.SW balance_sheet (annual, 2022-12-31) — Invested Capital: 121377000.00
ADVN.SW cash_flow (annual, 2022-12-31) — Investing Cash Flow: -3022000.00
ADVN.SW balance_sheet (annual, 2022-12-31) — Land And Improvements: 3539000.00
ADVN.SW balance_sheet (annual, 2022-12-31) — Long Term Capital Lease Obligation: 225000.00
ADVN.SW balance_sheet (annual, 2022-12-31) — Long Term Debt: 0.00
ADVN.SW balance_sheet (annual, 2022-12-31) — Long Term Debt And Capital Lease Obligation: 225000.00
ADVN.SW balance_sheet (annual, 2022-12-31) — Long Term Provisions: 1181000.00
ADVN.SW balance_sheet (annual, 2022-12-31) — Machinery Furniture Equipment: 112581000.00
ADVN.SW cash_flow (annual, 2022-12-31) — Net Common Stock Issuance: -5000.00
ADVN.SW income_statement (annual, 2022-12-31) — Net Income: -2348000.00
ADVN.SW income_statement (annual, 2022-12-31) — Net Income Common Stockholders: -2348000.00
ADVN.SW income_statement (annual, 2022-12-31) — Net Income Continuous Operations: -2348000.00
ADVN.SW income_statement (annual, 2022-12-31) — Net Income From Continuing And Discontinued Operation: -2348000.00
ADVN.SW income_statement (annual, 2022-12-31) — Net Income From Continuing Operation Net Minority Interest: -2348000.00
ADVN.SW cash_flow (annual, 2022-12-31) — Net Income From Continuing Operations: -2348000.00
ADVN.SW income_statement (annual, 2022-12-31) — Net Income Including Noncontrolling Interests: -2348000.00
ADVN.SW cash_flow (annual, 2022-12-31) — Net Intangibles Purchase And Sale: -101000.00
ADVN.SW income_statement (annual, 2022-12-31) — Net Interest Income: -48000.00
ADVN.SW cash_flow (annual, 2022-12-31) — Net Investment Purchase And Sale: 0.00
ADVN.SW cash_flow (annual, 2022-12-31) — Net Issuance Payments Of Debt: -339000.00
ADVN.SW cash_flow (annual, 2022-12-31) — Net Long Term Debt Issuance: -250000.00
ADVN.SW income_statement (annual, 2022-12-31) — Net Non Operating Interest Income Expense: -48000.00
ADVN.SW cash_flow (annual, 2022-12-31) — Net Other Financing Charges: -339000.00
ADVN.SW balance_sheet (annual, 2022-12-31) — Net PPE: 52447000.00
ADVN.SW cash_flow (annual, 2022-12-31) — Net PPE Purchase And Sale: 59000.00
ADVN.SW cash_flow (annual, 2022-12-31) — Net Short Term Debt Issuance: -89000.00
ADVN.SW balance_sheet (annual, 2022-12-31) — Net Tangible Assets: 120511000.00
ADVN.SW balance_sheet (annual, 2022-12-31) — Non Current Deferred Taxes Assets: 2296000.00
ADVN.SW balance_sheet (annual, 2022-12-31) — Non Current Deferred Taxes Liabilities: 2392000.00
ADVN.SW income_statement (annual, 2022-12-31) — Normalized EBITDA: 6820000.00
ADVN.SW income_statement (annual, 2022-12-31) — Normalized Income: -2752430.00
ADVN.SW cash_flow (annual, 2022-12-31) — Operating Cash Flow: 1563000.00
ADVN.SW income_statement (annual, 2022-12-31) — Operating Income: 534000.00
ADVN.SW income_statement (annual, 2022-12-31) — Operating Revenue: 178365000.00
ADVN.SW balance_sheet (annual, 2022-12-31) — Ordinary Shares Number: 730000.00
ADVN.SW balance_sheet (annual, 2022-12-31) — Other Current Liabilities: 4904000.00
ADVN.SW balance_sheet (annual, 2022-12-31) — Other Equity Interest: -58776000.00
ADVN.SW balance_sheet (annual, 2022-12-31) — Other Intangible Assets: 866000.00
ADVN.SW cash_flow (annual, 2022-12-31) — Other Non Cash Items: 1048000.00
ADVN.SW income_statement (annual, 2022-12-31) — Other Operating Expenses: 14764000.00
ADVN.SW balance_sheet (annual, 2022-12-31) — Other Properties: 23082000.00
ADVN.SW balance_sheet (annual, 2022-12-31) — Other Receivables: 4759000.00
ADVN.SW income_statement (annual, 2022-12-31) — Other Special Charges: -62000.00
ADVN.SW income_statement (annual, 2022-12-31) — Otherunder Preferred Stock Dividend: 0.00
ADVN.SW balance_sheet (annual, 2022-12-31) — Payables: 15502000.00
ADVN.SW balance_sheet (annual, 2022-12-31) — Prepaid Assets: 632000.00
ADVN.SW income_statement (annual, 2022-12-31) — Pretax Income: -532000.00
ADVN.SW balance_sheet (annual, 2022-12-31) — Properties: 0.00
ADVN.SW cash_flow (annual, 2022-12-31) — Provisionand Write Offof Assets: -566000.00
ADVN.SW cash_flow (annual, 2022-12-31) — Purchase Of Intangibles: -101000.00
ADVN.SW cash_flow (annual, 2022-12-31) — Purchase Of Investment: 0.00
ADVN.SW cash_flow (annual, 2022-12-31) — Purchase Of PPE: -2980000.00
ADVN.SW balance_sheet (annual, 2022-12-31) — Raw Materials: 13250000.00
ADVN.SW income_statement (annual, 2022-12-31) — Reconciled Cost Of Revenue: 101849000.00
ADVN.SW income_statement (annual, 2022-12-31) — Reconciled Depreciation: 7732000.00
ADVN.SW income_statement (annual, 2022-12-31) — Restructuring And Mergern Acquisition: 0.00
ADVN.SW balance_sheet (annual, 2022-12-31) — Retained Earnings: 85257000.00
ADVN.SW cash_flow (annual, 2022-12-31) — Sale Of Investment: 0.00
ADVN.SW cash_flow (annual, 2022-12-31) — Sale Of PPE: 59000.00
ADVN.SW income_statement (annual, 2022-12-31) — Selling And Marketing Expense: 3299000.00
ADVN.SW income_statement (annual, 2022-12-31) — Selling General And Administration: 8845000.00
ADVN.SW balance_sheet (annual, 2022-12-31) — Share Issued: 730000.00
ADVN.SW income_statement (annual, 2022-12-31) — Special Income Charges: 62000.00
ADVN.SW balance_sheet (annual, 2022-12-31) — Stockholders Equity: 121377000.00
ADVN.SW balance_sheet (annual, 2022-12-31) — Tangible Book Value: 120511000.00
ADVN.SW income_statement (annual, 2022-12-31) — Tax Effect Of Unusual Items: 37570.00
ADVN.SW income_statement (annual, 2022-12-31) — Tax Provision: 1816000.00
ADVN.SW income_statement (annual, 2022-12-31) — Tax Rate For Calcs: 0.09
ADVN.SW balance_sheet (annual, 2022-12-31) — Total Assets: 165634000.00
ADVN.SW balance_sheet (annual, 2022-12-31) — Total Capitalization: 121377000.00
ADVN.SW balance_sheet (annual, 2022-12-31) — Total Debt: 445000.00
ADVN.SW balance_sheet (annual, 2022-12-31) — Total Equity Gross Minority Interest: 121377000.00
ADVN.SW income_statement (annual, 2022-12-31) — Total Expenses: 177831000.00
ADVN.SW balance_sheet (annual, 2022-12-31) — Total Liabilities Net Minority Interest: 44257000.00
ADVN.SW balance_sheet (annual, 2022-12-31) — Total Non Current Assets: 55695000.00
ADVN.SW balance_sheet (annual, 2022-12-31) — Total Non Current Liabilities Net Minority Interest: 3798000.00
ADVN.SW income_statement (annual, 2022-12-31) — Total Operating Income As Reported: 596000.00
ADVN.SW income_statement (annual, 2022-12-31) — Total Other Finance Cost: 177000.00
ADVN.SW balance_sheet (annual, 2022-12-31) — Total Tax Payable: 2854000.00
ADVN.SW income_statement (annual, 2022-12-31) — Total Unusual Items: 442000.00
ADVN.SW income_statement (annual, 2022-12-31) — Total Unusual Items Excluding Goodwill: 442000.00
ADVN.SW balance_sheet (annual, 2022-12-31) — Treasury Stock: 0.00
ADVN.SW balance_sheet (annual, 2022-12-31) — Work In Process: 47269000.00
ADVN.SW balance_sheet (annual, 2022-12-31) — Working Capital: 69480000.00
ADVN.SW income_statement (annual, 2023-12-31) — +Operating Expense: 79499000.00
ADVN.SW income_statement (annual, 2023-12-31) — +Total Revenue: 169758000.00
ADVN.SW balance_sheet (annual, 2023-12-31) — Accounts Payable: 13605000.00
ADVN.SW balance_sheet (annual, 2023-12-31) — Accounts Receivable: 23684000.00
ADVN.SW balance_sheet (annual, 2023-12-31) — Accumulated Depreciation: -140400000.00
ADVN.SW balance_sheet (annual, 2023-12-31) — Allowance For Doubtful Accounts Receivable: -1337000.00
ADVN.SW income_statement (annual, 2023-12-31) — Amortization: 805000.00
ADVN.SW cash_flow (annual, 2023-12-31) — Amortization Cash Flow: 805000.00
ADVN.SW income_statement (annual, 2023-12-31) — Basic Average Shares: 730000.00
ADVN.SW income_statement (annual, 2023-12-31) — Basic EPS: -5.27
ADVN.SW cash_flow (annual, 2023-12-31) — Beginning Cash Position: 28601000.00
ADVN.SW balance_sheet (annual, 2023-12-31) — Buildings And Improvements: 51734000.00
ADVN.SW cash_flow (annual, 2023-12-31) — Capital Expenditure: -6223000.00
ADVN.SW cash_flow (annual, 2023-12-31) — Capital Expenditure Reported: -5891000.00
ADVN.SW balance_sheet (annual, 2023-12-31) — Capital Lease Obligations: 459000.00
ADVN.SW balance_sheet (annual, 2023-12-31) — Capital Stock: 14600000.00
ADVN.SW balance_sheet (annual, 2023-12-31) — Cash And Cash Equivalents: 27304000.00
ADVN.SW balance_sheet (annual, 2023-12-31) — Cash Cash Equivalents And Short Term Investments: 27304000.00
ADVN.SW balance_sheet (annual, 2023-12-31) — Cash Equivalents: 12610000.00
ADVN.SW balance_sheet (annual, 2023-12-31) — Cash Financial: 14694000.00
ADVN.SW cash_flow (annual, 2023-12-31) — Change In Inventory: 6197000.00
ADVN.SW cash_flow (annual, 2023-12-31) — Change In Other Current Liabilities: -8412000.00
ADVN.SW cash_flow (annual, 2023-12-31) — Change In Payable: 1513000.00
ADVN.SW cash_flow (annual, 2023-12-31) — Change In Prepaid Assets: -5000.00
ADVN.SW cash_flow (annual, 2023-12-31) — Change In Receivables: 391000.00
ADVN.SW cash_flow (annual, 2023-12-31) — Change In Working Capital: -311000.00
ADVN.SW cash_flow (annual, 2023-12-31) — Changes In Cash: -745000.00
ADVN.SW balance_sheet (annual, 2023-12-31) — Common Stock: 14600000.00
ADVN.SW balance_sheet (annual, 2023-12-31) — Common Stock Equity: 114471000.00
ADVN.SW balance_sheet (annual, 2023-12-31) — Construction In Progress: 4411000.00
ADVN.SW income_statement (annual, 2023-12-31) — Cost Of Revenue: 91989000.00
ADVN.SW balance_sheet (annual, 2023-12-31) — Current Assets: 95033000.00
ADVN.SW balance_sheet (annual, 2023-12-31) — Current Capital Lease Obligation: 96000.00
ADVN.SW balance_sheet (annual, 2023-12-31) — Current Debt: 0.00
ADVN.SW balance_sheet (annual, 2023-12-31) — Current Debt And Capital Lease Obligation: 96000.00
ADVN.SW balance_sheet (annual, 2023-12-31) — Current Liabilities: 32284000.00